Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
05 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251205363745/en/Amylyx-Pharmaceuticals-Announces-New-Safety-and-Tolerability-Cohort-1-Data-of-AMX0114-in-ALS-from-First-in-Human-LUMINA-Trial
06 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251106437649/en/Amylyx-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results
03 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251103271379/en/Amylyx-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences
30 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251030438814/en/Amylyx-Pharmaceuticals-to-Report-Third-Quarter-2025-Financial-Results-on-November-6-2025
22 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-amylyx-pharmaceuticals-inc-to-contact-law-firm-302591570.html
09 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250909149204/en/Amylyx-Pharmaceuticals-Announces-Pricing-of-%24175-Million-Underwritten-Public-Offering-of-Common-Stock
Drugs in Development
Details:
The net proceeds will be used for the future development of Avexitide, a novel, first-in-class GLP-1 receptor antagonist with the potential to treat post-bariatric hypoglycemia.
Lead Product(s): Avexitide
Therapeutic Area: Endocrinology Brand Name: Exendin 9-39
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Leerink Partners
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 10, 2025
Lead Product(s) : Avexitide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Leerink Partners
Deal Size : $175.0 million
Deal Type : Public Offering
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering
Details : The net proceeds will be used for the future development of Avexitide, a novel, first-in-class GLP-1 receptor antagonist with the potential to treat post-bariatric hypoglycemia.
Product Name : Exendin 9-39
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
September 10, 2025
Details:
AMX0114 is an investigational antisense oligonucleotide (ASO) targeting calpain-2 (CAPN2) for the potential treatment of amyotrophic lateral sclerosis (ALS).
Lead Product(s): AMX0114
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2025
Amylyx Doses First ALS Patient in Phase 1 LUMINA Trial of AMX0114
Details : AMX0114 is an investigational antisense oligonucleotide (ASO) targeting calpain-2 (CAPN2) for the potential treatment of amyotrophic lateral sclerosis (ALS).
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 09, 2025
Details:
AMX0114 is an investigational antisense oligonucleotide (ASO) targeting calpain-2 (CAPN2) for the potential treatment of amyotrophic lateral sclerosis (ALS).
Lead Product(s): AMX0114
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 21, 2025
Amylyx Pharmaceuticals Announces Clinical Hold Lifted on AMX0114 Trial for ALS
Details : AMX0114 is an investigational antisense oligonucleotide (ASO) targeting calpain-2 (CAPN2) for the potential treatment of amyotrophic lateral sclerosis (ALS).
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 21, 2025
Details:
The net proceeds will used to support the company's late-stage product Exendin 9-39 (avexitide). It is being evaluated for the treatment of Post Bariatric Hypoglycemia.
Lead Product(s): Avexitide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Leerink Partners
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 10, 2025
Lead Product(s) : Avexitide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Leerink Partners
Deal Size : $60.0 million
Deal Type : Public Offering
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Details : The net proceeds will used to support the company's late-stage product Exendin 9-39 (avexitide). It is being evaluated for the treatment of Post Bariatric Hypoglycemia.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
January 10, 2025
Details:
The net proceeds will used to support the company's late-stage product Exendin 9-39 (avexitide). It is being evaluated for the treatment of Post Bariatric Hypoglycemia.
Lead Product(s): Avexitide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Leerink Partners
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering January 09, 2025
Lead Product(s) : Avexitide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Leerink Partners
Deal Size : Undisclosed
Deal Type : Public Offering
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
Details : The net proceeds will used to support the company's late-stage product Exendin 9-39 (avexitide). It is being evaluated for the treatment of Post Bariatric Hypoglycemia.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
January 09, 2025
Details:
Avexitide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Post-Bariatric, Hypoglycemia.
Lead Product(s): Avexitide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 24, 2024
Lead Product(s) : Avexitide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Avexitide for Treatment of Post-Bariatric Hypoglycemia
Details : Avexitide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Post-Bariatric, Hypoglycemia.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 24, 2024
Details:
Amylyx Pharmaceuticals acquires Eiger BioPharmaceuticals' experimental drug Avexitide, GLP-1 antagonist. Currently, it is being evaluated for the treatment of Post Bariatric Hypoglycemia.
Lead Product(s): Avexitide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2024
Lead Product(s) : Avexitide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Unveils Phase 3 LUCIDITY Trial Design for Avexitide in Post-Bariatric Hypoglycemia
Details : Amylyx Pharmaceuticals acquires Eiger BioPharmaceuticals' experimental drug Avexitide, GLP-1 antagonist. Currently, it is being evaluated for the treatment of Post Bariatric Hypoglycemia.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 04, 2024
Details:
AMX0114 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Lead Product(s): AMX0114
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 30, 2024
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
Details : AMX0114 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 30, 2024
Details:
Relyvrio (taurursodiol and sodium phenylbutyrate) is a glutamine chelator small molecule drug candidate, being evaluated for the treatment of wolfram syndrome.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 17, 2024
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Announces Positive Phase 2 Results of AMX0035 For Wolfram Syndrome
Details : Relyvrio (taurursodiol and sodium phenylbutyrate) is a glutamine chelator small molecule drug candidate, being evaluated for the treatment of wolfram syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2024
Details:
Relyvrio (taurursodiol and sodium phenylbutyrate) is a glutamine chelator small molecule drug candidate, being evaluated for the treatment of wolfram syndrome.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 02, 2024
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Pharmaceuticals Receives Orphan Drug Designation for AMX0035 in Wolfram Syndrome
Details : Relyvrio (taurursodiol and sodium phenylbutyrate) is a glutamine chelator small molecule drug candidate, being evaluated for the treatment of wolfram syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 02, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
